10-K: Pure Bioscience Faces Going Concern Doubt Amidst Financial Challenges

PURE Bioscience, Inc. (PURE) filed its annual report, highlighting significant financial challenges including recurring losses and a substantial accumulated deficit, raising doubts about its ability to continue as a going concern.

Summary

• PURE Bioscience, Inc. (PURE) has filed its annual report for the fiscal year ended July 31, 2026.
• The company continues to face significant financial challenges, with recurring losses and a substantial accumulated deficit of $141.5 million as of July 31, 2026.
• These financial conditions raise substantial doubt about the company's ability to continue as a going concern.
• Net revenue for the fiscal year was $2.32 million, with a net loss of $2.48 million.
• The company's cash balance was $569,000 as of July 31, 2026, which is insufficient to meet anticipated needs over the next twelve months, necessitating additional capital raises.
• The company's core technology is Silver Dihydrogen Citrate (SDC), an antimicrobial agent used in products like PURE Hard Surface and PURE Control.
• The company is subject to various regulatory approvals, particularly for PURE Control in food processing.
• Significant convertible notes payable to related parties, totaling $5.8 million as of July 31, 2026, are outstanding, with $1.015 million past due.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's ongoing financial struggles, substantial doubt about its ability to continue as a going concern, and significant accumulated deficit, despite its innovative technology.

Positives

• The company's SDC technology is described as a broad-spectrum, non-toxic antimicrobial agent with superior efficacy, reduced toxicity, and resistance to bacterial resistance.
• PURE Hard Surface is EPA-registered and effective against a wide range of pathogens, including resistant strains and viruses.
• PURE Control has received FDA approval for poultry and produce processing, with specific USDA approval for poultry processing pending.
• The company has a zero-waste manufacturing process for SDC-based products.
• The company has a dedicated team and maintains positive employee relations.
• The company has a strategy to grow its distribution network and explore new markets and applications for its technology.

Negatives

• The company has a history of recurring losses and a cumulative net loss of $141.5 million as of July 31, 2026.
• Substantial doubt exists about the company's ability to continue as a going concern due to insufficient working capital and ongoing losses.
• The company will need to raise additional capital, which may result in significant dilution to existing stockholders.
• As of July 31, 2026, $1.015 million in convertible notes payable to related parties were past due.
• The company's SDC-based products are generally more expensive to produce than existing chemicals, potentially hindering market adoption.
• The company has limited sales, marketing, and product distribution experience.
• The company is dependent on a third-party manufacturer (ICC) for its SDC-based products.
• The company's common stock is traded on the OTCQB, which offers less liquidity than national exchanges and may be considered penny stock.

Risks

• The company has limited capital and will need to raise additional capital in the future, which may cause dilution or restrict operations.
• The company has a history of losses and may not achieve or maintain profitability.
• Failure to increase customer awareness and adoption of PURE Hard Surface and PURE Control could harm the business.
• Inability to correctly estimate future revenues and operating expenses could lead to cash shortfalls and require earlier financing.
• Quarterly operating results may vary, negatively affecting the market price of common stock.
• Delays or failure to obtain required regulatory approvals from the FDA and USDA for PURE Control could harm commercialization efforts.
• Loss of one or more key customers could adversely affect the business, as one customer accounted for 24% of net product sales in FY2026.
• Dependence on the core SDC technology and failure to achieve market acceptance could prevent profitability.

Future Outlook

The company's future outlook is heavily dependent on its ability to secure additional financing to fund operations and implement its business plan. Success in commercializing its SDC-based products, particularly PURE Control, and expanding market adoption are critical. The company anticipates continued losses in future periods and faces ongoing challenges related to competition, regulatory approvals, and market acceptance.

Management Comments

• "We are dedicated to developing and commercializing proprietary antimicrobial products that address health and environmental challenges related to pathogen and hygienic control."
• "Our goal is to establish a sustainable company by commercializing SDC-based products developed through our proprietary technology platform."
• "We believe our SDC-based products offer superior pathogen control compared to traditional chemical solutions, which often have higher toxicity."
• "Our success depends on our ability to continue to increase customer awareness and adoption of our food safety product offerings, PURE Hard Surface and PURE Control."

Industry Context

StockSavvy.ai notes that PURE Bioscience operates in the highly competitive food safety and antimicrobial market, facing established players with greater resources. The company's SDC technology offers a potentially differentiated, less toxic alternative to traditional chemical disinfectants, aligning with growing market demand for safer and more environmentally friendly solutions.

Comparison to Industry Standards

• PURE Hard Surface is rated in EPA Toxicity Category IV (no signal word required), significantly lower than traditional disinfectants which fall into Categories I and II.
• PURE Control demonstrated up to a 6 log reduction in Salmonella on treated poultry products, a significant efficacy metric in food processing.
• The company's SDC technology aims to displace traditional chemicals like peracetic acid, acidified sodium chlorite, ozone, and chlorine dioxide, which often carry warning labels and can negatively affect processing environments.
• The company's products are registered with the EPA, FDA, and Health Canada, meeting regulatory standards for efficacy, toxicity, and labeling.

Corporate Governance

Legal Proceedings

• The company is not currently aware of any material lawsuits or legal proceedings that would have a material adverse effect on its business, financial condition, or results of operations.

Related Party Transactions

• Tom Y. Lee, a Board member, invested $970,000 in the 2026 Note Purchase Agreement.
• Tom Y. Lee invested $500,000 in the 2025 Note Purchase Agreement and an additional $1,500,000 in subsequent closings.
• Tom Y. Lee invested $500,000 in the March 2024 Note Purchase Agreement and an additional $500,000 in a subsequent closing.
• Tom Y. Lee invested $1,000,000 and Ivan Chen invested $15,000 in the July 2023 Note Purchase Agreement, with Mr. Lee investing an additional $785,000 later.
• Tom Y. Lee invested approximately $700,000 and Ivan Chen invested $27,650 in the April 30, 2026 private placement financing.
• As of July 31, 2026, $1.015 million in principal was outstanding under the 2023 Notes, which are past due.
• As of July 31, 2026, $1.785 million was outstanding under the 2024 Notes.
• As of July 31, 2026, $2.0 million was outstanding under the 2025 Notes.
• As of July 31, 2026, $970,000 was outstanding under the 2026 Notes.

Stakeholder Impact

• Shareholders: Potential for significant dilution due to future capital raises, volatility in stock price, and the company's going concern status.
• Creditors: Risk associated with the company's ability to repay outstanding convertible notes, with $1.015 million past due as of July 31, 2026.
• Employees: Potential impact on job security if the company cannot secure financing or achieve profitability.
• Customers: Continued access to innovative food safety solutions, but potential concerns about supplier stability.
• Suppliers: Potential impact on payment timeliness given the company's liquidity challenges.

Next Steps

• Secure additional capital to fund operations and implement the business plan.
• Continue to increase customer awareness and adoption of PURE Hard Surface and PURE Control.
• Seek required regulatory approvals, particularly from the USDA for PURE Control in poultry processing.
• Grow and support the distribution network.
• Continue to partner with third parties for international product approvals and commercialization.
• Develop additional proprietary products and applications leveraging the SDC technology platform.
• Protect and enhance intellectual property rights.

Key Dates

Recommendation

While PURE Bioscience possesses innovative technology in the growing food safety market, its significant financial challenges, including a going concern warning and substantial debt, warrant a cautious approach. The company's ability to secure necessary funding and achieve profitability remains a key uncertainty. Investors should monitor future financing activities and regulatory progress closely.

Keywords

PURE Bioscience, SDC technology, food safety, antimicrobial, PURE Hard Surface, PURE Control, going concern, capital raise